

DAFTAR PUSTAKA

1. Song Y Da, Bai XM, Ma J. The association of systemic immuneinflammation index with lung function, risk of COPD and COPD severity: A population-based study. *PLoS One*. 2024;19(6):1-23.
2. Ye C, Yuan L, Wu K, Shen B, Zhu C. Association between systemic immune-inflammation index and chronic obstructive pulmonary disease: a population-based study. *BMC Pulm Med*. 2023;23(295):1-12.
3. Li M, Cheng K, Ku K, Li J, Hu H, Ung COL. Factors Influencing the Length of Hospital Stay Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in Macao Population: A Retrospective Study of Inpatient Health Record. *Int J Chron Obstruct Pulmon Dis*. 2021;16:1677-85.
4. Fazleen A, Wilkinson T. Early COPD: current evidence for diagnosis and management. *Ther Adv Respir Dis*. 2020;14:1-13.
5. Anggraeni M, Russilawati, Ermayanti S. Faktor – Faktor yang Mempengaruhi Kejadian Gagal Napas pada Pasien PPOK Eksaserbasi Akut di RSUP Dr. M. Djamil Padang. *J Ilmu Kesehat Indones*. 2020;1(1):1-6.
6. Wang Q, Pei G, Chen L, He Z. Factors affecting the length of stay and hospital readmission rates after an acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. *Ann Transl Med*. 2022;10(4):1-9.
7. Sethi S, Make BJ, Robinson SB, Kumar S, Pollack M, Moretz C, et al. Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population. *Int J Chron Obstruct Pulmon Dis*. 2022;17:593-608.
8. Hurst JR, Skolnik N, Hansen GJ, Anzueto A, Donaldson GC, Dransfield MT, et al. Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. *Eur J Intern Med*. 2020;73:1-6.
9. Apriningsih H, Sutanto YS, Reviono R, Adhiputri A, Prasetya W, Fahlevie

- F, et al. The Degree of Inflammation and Length of Hospital Stay in Acute Exacerbation of COPD Patients After Secretome Administration. *J Respirologi Indones*. 2023;43(1):15-21.
10. Fayiad H, Amer AM. Predictive role of platelets to lymphocytes ratio and neutrophil to lymphocytes ratio in COPD exacerbation. *Egypt J Intern Med*. 2024;36(71):1-6.
 11. Vural S, Muhtaroglu A, Güngör M. Systemic immune-inflammation index: A new marker in differentiation of different thyroid diseases. *Med*. 2023;102(31):1-5.
 12. Kanter E, Payza U, Coşkun S, Kaymaz E. The Prognostic Importance of the Systemic Immune Inflammation Index (SII) in Patients with Chronic Obstructive Pulmonary Disease (COPD). *CJMR*. 2023;3(2):43-52.
 13. Geng Y, Shao Y, Zhu D, Zheng X, Zhou Q, Zhou W, et al. Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis. *Sci Rep*. 2016;6:1-9.
 14. Zhang Y, Tan X, Hu S, Cui Z, Chen W. Relationship Between Systemic Immune-Inflammation Index and Risk of Respiratory Failure and Death in COPD: A Retrospective Cohort Study Based on the MIMIC-IV Database. *Int J Chron Obstruct Pulmon Dis*. 2024;19:459-73.
 15. Celtikci B, Gulensoy ES. Prognostic importance of systemic immune inflammation index in chronic obstructive pulmonary disease. *Acta Medica Cordoba*. 2023;54(3):226-34.
 16. PDPI. *Penyakit Paru Obstruktif Kronis (PPOK) Pedoman Diagnosis & Penatalaksanaan Di Indonesia*. Edisi 3. Jakarta; 2023. h.1-166.
 17. Guo-parke H, Linden D, Weldon S, Kidney JC, Taggart CC. Mechanisms of Virus-Induced Airway Immunity Dysfunction in the Pathogenesis of COPD Disease, Progression, and Exacerbation. *Front Immunol*. 2020;11:1-10.
 18. Ritchie AI, Wedzicha JA. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. *Clin Chest Med*. 2020;41(3):421-38.

19. GOLD. Global Initiative for Chronic Obstructive Lung. Global Strategy for The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2025 Report). Published online 2024:1-122.
20. MacLeod M, Papi A, Contoli M, Beghe B, Celli BR, Wedzicha JA, et al. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. *Respirology*. 2021;26(6):532-51.
21. Co MH, Hobbs BD, Silverman EK. The Genetics of COPD. *Lancet Respir Med*. 2022;10(5):485-96.
22. Aghapour M, Ubags ND, Bruder D, Hiemstra PS, Sidhaye V, Rezaee F, et al. Role of air pollutants in airway epithelial barrier dysfunction in asthma and COPD. *Eur Respir Rev*. 2023;31(163):1-19.
23. Celli B, Fabbri L, Criner G, Martinez FJ, Mannino D, Vogelmeier C, et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision. *Am J Respir Crit Care Med*. 2022;206(11):1317-25.
24. Sandelowsky H, Weinreich UM, Aarli BB, Sundh J, Hoines K, Stratelis G, et al. COPD - do the right thing. *BMC Fam Pract*. 2021;22(244):1-17.
25. Barnes PJ, Burney PGJ, Silverman EK, Celli BR, Vestbo J, Wedzicha JA, et al. Chronic obstructive pulmonary disease. *Nat Rev Dis Prim*. 2015;1:1-21.
26. Basille D, Soriot L, Weppe F, Desmettres P, Henriques P, Benoit N, et al. Association between acute exacerbation of chronic obstructive pulmonary disease and short-term exposure to ambient air pollutants in France. *Environ Heal A Glob Access Sci Source*. 2024;23(107):1-9.
27. Li N, Ma J, Ji K, Wang L. Association of PM_{2.5} and PM₁₀ with Acute Exacerbation of Chronic Obstructive Pulmonary Disease at lag₀ to lag₇: A Systematic Review and Meta-Analysis. *COPD J Chronic Obstr Pulm Dis*. 2022;19(1):243-54.
28. Karkra R, Krishnarao CS, Siddaiah JB, Anand MP. Hematological Parameters for Predicting Mortality in Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *J Clin Med*. 2023;12:1-10.
29. Kim GD, Lim EY, Shin HS. Macrophage Polarization and Functions in

- Pathogenesis of Chronic Obstructive Pulmonary Disease. *Int J Mol Sci.* 2024;25(11):1-29.
30. Hikichi M, Mizumura K, Maruoka S, Gon Y. Pathogenesis of chronic obstructive pulmonary disease (COPD) induced by cigarette smoke. *J Thorac Dis.* 2019;11(17):2129-40.
 31. Xu J, Zeng Q, Li S, Su Q, Fan H. Inflammation mechanism and research progress of COPD. *Front Immunol.* 2024;15:1-11.
 32. Talman S, Djamin RS, Grootenboers MJJH, Aerts JGJV, Eerden MM Van Der. Mediators Of Inflammation In COPD. *J Pulm Med Respir Res.* 2019;5(26):1-10.
 33. Garth J, Barnes JW, Krick S. Targeting Cytokines as Evolving Treatment Strategies in Chronic Inflammatory Airway Diseases. *Int J Mol Sci.* 2018;19(11):1-19.
 34. Upadhyay P, Wu CW, Pham A, Zeki AA, Royer CM, Kodavanti UP, et al. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease (COPD). *J Toxicol Environ Heal - Part B Crit Rev.* 2023;26(5):275-305.
 35. Duan RR, Hao K, Yang T. Air pollution and chronic obstructive pulmonary disease. *Chronic Dis Transl Med.* 2020;6:260-9.
 36. Sheng F, Chen L, Lin H, Wu H. Systematic review and meta-analysis: value of venous blood gas in the diagnosis of acute exacerbation of chronic obstructive pulmonary disease in Emergency Department. *Ann Palliat Med.* 2022;11(4):1473-81.
 37. Celli BR, Fabbri LM, Aaron SD, Agusti A, Brook R, Criner GJ, et al. An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: The rome proposal. *Am J Respir Crit Care Med.* 2021;204(11):1251-8.
 38. Hoge SP, Tudorache E, Fildan AP, Fira-Mladinescu O, Marc M, Oancea C. Risk factors of chronic obstructive pulmonary disease exacerbations. *Clin Respir J.* 2020;14(3):183-97.
 39. Zheng F, Wang X. Effect of pneumonia on the outcomes of acute

- exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis. *BMC Pulm Med*. 2024;24(1):1-14.
40. Yu Y, Liu W, Jiang HL, Mao B. Pneumonia Is Associated with Increased Mortality in Hospitalized COPD Patients: A Systematic Review and Meta-Analysis. *Respiration*. 2021;100(1):64-76.
 41. Chen YH, Sun YC. Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: Implications and Future Research. *Chin Med J (Engl)*. 2016;129(17):2017-9.
 42. Mou K, Chan SMH, Vlahos R. Musculoskeletal crosstalk in chronic obstructive pulmonary disease and comorbidities: Emerging roles and therapeutic potentials. *Pharmacol Ther*. 2024;257:1-28.
 43. Matsunaga K, Harada M, Suizu J, Oishi K, Asami-Noyama M, Hirano T. Comorbid conditions in chronic obstructive pulmonary disease: Potential therapeutic targets for unmet needs. *J Clin Med*. 2020;9(10):1-20.
 44. Kahnert K, Jörres RA, Behr J, Welte T. The Diagnosis and Treatment of COPD and Its Comorbidities. *Dtsch Arztebl Int*. 2023;120(25):434-44.
 45. Wu S, Liu X, Yue W, Hu K. Prognosis of OSA-COPD overlap syndrome: A matter of concern. *Sleep Res*. 2025;(9):1-10.
 46. Lonergan M, Dicker AJ, Crichton ML, Keir HR, Dyke MKV, Mullerova H, et al. Blood neutrophil counts are associated with exacerbation frequency and mortality in COPD. *Respir Res*. 2020;21(166):1-10.
 47. Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res*. 2014;20(23):6212-22.
 48. Ma J, Li K. Systemic immune-inflammation index is associated with coronary heart disease: a cross-sectional study of NHANES 2009–2018. *Front Cardiovasc Med*. 2023;10:1-8.
 49. Luo J, Qin X, Zhang X, Zhang Y, Yuan F, Shi W, et al. Prognostic implications of systemic immune-inflammation index in myocardial infarction patients with and without diabetes: insights from the NOAFCAMI-SH registry. *Cardiovasc Diabetol*. 2024;23(41):1-11.

50. Ye Z, Hu T, Wang J, Xio R, Liao X, Liu M, et al. Systemic immune-inflammation index as a potential biomarker of cardiovascular diseases: A systematic review and meta-analysis. *Front Cardiovasc Med*. 2022;9:1-14.
51. Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab. *J Clin Lab Anal*. 2019;33(8):1-8.
52. Wang D, Guo D, Shi F, Zhu Y, Li A, Kong L, et al. The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer. *Futur Oncol*. 2019;15(29):3367-79.
53. Kwok WC, Tam TCC, Lam DCL, Ip MSM, Ho JCM. Systemic immune-inflammation index in predicting hospitalized bronchiectasis exacerbation risks and disease severity. *J Thorac Dis*. 2024;16(5):2767-75.
54. Tortum F, Tekin E, Ozdal E. Use of the systemic immune-inflammation index to predict the severity of pneumonia in the emergency department. *Med Res J*. 2023;8(3):186-91.
55. Sari AP, Ratnawati R, Aniwidyaningsih W, Andarini SL, Yunus F. Neutrophyl – Lymphocyte Ratio (NLR) and C-Reactive Protein (CRP) Levels in Stable and Exacerbated Chronic Obstructive Pulmonary Disease (COPD) Patients in Persahabatan Hospital Jakarta. *Respir Sci*. 2022;2(2):78-91.
56. Aini QSH, Adrianison A, Fridayenti F. Gambaran Jumlah Neutrofil Darah Tepi Pasien Penyakit Paru Obstruktif Kronik (PPOK) di Ruang Rawat Inap RSUD Arifin Achmad Provinsi Riau Tahun 2017. *J Ilmu Kedokt*. 2019;13(2):134-40.
57. Moon SW, Leem AY, Kim YS, Lee JH, Kim TH, Oh YM, et al. Low serum lymphocyte level is associated with poor exercise capacity and quality of life in chronic obstructive pulmonary disease. *Sci Rep*. 2020;10(1):1-8.
58. Xu Y, Yan Z, Li K, Liu L. The association between systemic immune-inflammation index and chronic obstructive pulmonary disease in adults aged 40 years and above in the United States: a cross-sectional study based

- on the NHANES 2013–2020. *Front Med*. 2023;10:1-9.
59. Qin K, Xu B, Pang M, Wang H, Yu B. The functions of CD4 T-helper lymphocytes in chronic obstructive pulmonary disease. *Acta Biochim Biophys Sin (Shanghai)*. 2022;54(2):173-8.
 60. Wechsler ME, Wells JM. What Every Clinician Should Know About Inflammation in COPD. *ERJ Open Res*. 2024;10(5):1-17.
 61. Freeman CM, Martinez CH, Todt JC, Martinez JJ, Han MK, Thompson DL, et al. Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. *Respir Res*. 2015;16(94):1-14.
 62. Mallah H, Ball S, Sekhon J, Parmar K, Nugent K. Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy. *Respir Med*. 2020;171:1-6.
 63. Rayes J, Bourne JH, Brill A, Watson SP. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. *Res Pract Thromb Haemost*. 2020;4(1):23-35.
 64. van der Vorm LN, Li L, Huskens D, Hulstein JJJ, Roest M, de Groot PG, et al. Acute exacerbations of COPD are associated with a prothrombotic state through platelet-monocyte complexes, endothelial activation and increased thrombin generation. *Respir Med*. 2020;171:1-8.
 65. Du D, Zhang G, Xu D, Liu L, Hu X, Zeng T, et al. Association between systemic inflammatory markers and chronic obstructive pulmonary disease: A population-based study. *Heliyon*. 2024;10:1-10.
 66. Benz E, Wijnant SRA, Trajanoska K, Arinze JT, de Roos EW, de Ridder M, et al. Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study. *ERJ Open Res*. 2022;8:1-12.
 67. Crisafulli E, Ielpo A, Barbetta E, Ceccato A, Huerta A, Gabbarus A, et al. Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary

- disease: A prospective study. *Respir Res.* 2018;19(261):1-12.
68. Parmana IMA, Boom CE, Poernomo H, Gani C, Nugroho B, Cintyandy R, et al. Systemic Immune-Inflammation Index Predicts Prolonged Mechanical Ventilation and Intensive Care Unit Stay After off-Pump Coronary Artery Bypass Graft Surgery: A Single-Center Retrospective Study. *Vasc Health Risk Manag.* 2023;19:353-61.
69. Ari M, Ozdemir T, Yildiz M, Celik D, Usul E, Ari E, et al. Factors Affecting the Length of Hospital Stay in Hypercapnic Respiratory Failure. *Diagnostics.* 2025;15(14):1-10.
70. Jo YS, Rhee CK, Kim KJ, Yoo KH, Park YB. Risk factors for early readmission after acute exacerbation of chronic obstructive pulmonary disease. *Ther Adv Respir Dis.* 2020;14:1-11.
71. Gao F, He S, Li J, Wang X, Chen X, Bu X. The Association Between Systemic Immune-Inflammation Index at Admission and Readmission in Patients with Bronchiectasis. *J Inflamm Res.* 2024;17:6051-61.
72. Cheng SL, Lin CH. COPD guidelines in the Asia-Pacific Regions: Similarities and Differences. *Diagnostics.* 2021;11:1-11.
73. K KK, Bhushanarao C, Praveen J V, Dilleshwara RP. The Use of Cauda-70 Score in Predicting the Prognosis in Patients with Acute Exacerbations of COPD. *IOSR J Dent Med Sci e-ISSN.* 2022;21(10):21-5.
74. Jo YS, Kim KJ, Rhee CK, Yoo KH, Jung KS, Park YB. Prevalence, characteristics, and risk of exacerbation in young patients with chronic obstructive pulmonary disease. *Respir Res.* 2022;23(1):1-8.
75. Zhu D, Zhao G, Wang X. Association of Smoking and Smoking Cessation With Overall and Cause-Specific Mortality. *Am J Prev Med.* 2021;60(4):504-12.
76. Kramarow EA. Health of Former Cigarette Smokers Aged 65 and Over: United States. *Natl Health Stat Report.* 2020;145:1-11.
77. Ly K, Wakefield D, ZuWallack R. The usefulness of Charlson Comorbidity Index (CCI) scoring in predicting all-cause mortality in Outpatients with Clinical Diagnoses of COPD. *J Multimorbidity Comorbidity.* 2025;15:1-7.

78. Ruan H, Zhang H, Wang J, Zhao H, Han W, Li J. Readmission rate for acute exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Respir Med*. 2023;206:1-12.
79. Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. *Lancet Respir Med*. 2022;10(5):447-58.
80. Aprilen N, Indratama IMB. Profile of chronic obstructive pulmonary disease (COPD) patients in Oksibil Regional Public Hospital at 2020. *J Penyakit Dalam Udayana*. 2022;6(1):10-4.
81. Santus P, Di Marco FD, Braidò F, Contoli M, Corsico AG, Micheletto C, et al. Exacerbation Burden in COPD and Occurrence of Mortality in a Cohort of Italian Patients: Results of the Gulp Study. *Int J COPD*. 2024;19:607-17.
82. Chaurasiya PS, Lamsal DK, Khatri A, Aryal L. Impact of clinical factors on hospital stay and hospital readmission rate after acute exacerbation of COPD: a retrospective cross-sectional study. *F1000Research*. 2023;12(64):1-12.
83. Muhammad FF, Abdurrahim F, Gunawan JP, Rahma MT, Oktaviana TA, Antriandarti E. Analysis study: pengaruh faktor AHH (angka harapan hidup) pada masyarakat Provinsi Jawa Tengah tahun 2013-2021. *Kemakmuran Hijau J Ekon Pembang*. 2024;1(1):11-22.
84. Lüthi-Corridori G, Boesing M, Ottensarendt N, Leuppi-Taegtmeyer AB, Schuetz P, Leuppi JD, et al. Predictors of Length of Stay, Rehospitalization and Mortality in COPD Patients: A Retrospective Cohort Study. *J Clin Med*. 2023;12:1-14.
85. Kukrety SP, Parekh JD, Bailey KP. Chronic obstructive pulmonary disease and the hallmarks of aging. *Lung India*. 2018;35(1):321-7.
86. Tandela T, Prasetya DY, Sari TP. Evaluasi Penggunaan Obat dan Hasil Terapi pada Pasien Paru Obstruktif Kronik (PPOK) di Instalasi Rawat Jalan RSUD Waluyo Jati Kraksaan. *Java Heal J*. 2023;10(2):1-23.
87. Guptha IDGAS, Artana IGNB, Purnamasidhi CAWP, Mariadi IK. Faktor-

faktor yang berpengaruh terhadap kematian akibat penyakit paru obstruktif kronis eksaserbasi akut di Rumah Sakit Ngoerah. *Intisari Sains Medis*. 2025;16(1):97-102.

88. Nurwulandari NU, Zazuli Z, Wihastuti R, Wikaningtyas P. Factors affecting the outcomes in stable chronic obstructive pulmonary disease patients at an Army Central Hospital. *Pharm Pract (Granada)*. 2024;22(1):1-16.
89. Candra A, Santi TD, Maidayani M. Faktor-Faktor yang Berhubungan dengan Derajat Merokok pada Laki-Laki Usia 26-45 Tahun di Aceh Besar. *Media Kesehat Masy Indones*. 2023;22(2):100-4.
90. Kotlyarov S. The Role of Smoking in the Mechanisms of Development of Chronic Obstructive Pulmonary Disease and Atherosclerosis. *Int J Mol Sci*. 2023;24(10):1-26.
91. Kiani FZ, Ahmadi A. Prevalence of different comorbidities in chronic obstructive pulmonary disease among Shahrekord PERSIAN cohort study in southwest Iran. *Sci Rep*. 2021;11:1-8.
92. Santos NC dos, Miravittles M, Camelier AA, Almeida VDC de, Maciel RRBT, Camelier FWR. Prevalence and impact of comorbidities in individual with COPD: a systematic review. *Tuberc Respir Dis (Seoul)*. 2022;85:205-20.
93. Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, et al. Acute exacerbation of COPD. *Respirology*. 2016;21(7):1152-65.
94. Zeng J, Zhou C, Yi Q, Luo Y, Wei H, Ge H, et al. Validation of the Rome Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbation: A Multicenter Cohort Study. *Int J COPD*. 2024;19:193-204.
95. Whittaker H, Rubino A, Müllerová H, Morris T, Varghese P, Xu Y, et al. Frequency and Severity of Exacerbations of COPD Associated with Future Risk of Exacerbations and Mortality: A UK Routine Health Care Data Study. *Int J COPD*. 2022;17:427-37.
96. Michael J, Mathew S, Vincent J. Airflow limitation in asymptomatic tobacco users and tobacco non-smokers. *Natl J Physiol Pharm Pharmacol*. 2024;14(3):440-3.

97. Dave C, Wharton S, Mukherjee R, Faqihi BM, Stockley RA, Turner AM. Development and Relevance of Hypercapnia in COPD. *Can Respir J*. 2021;2021:1-8.
98. O'Donnell DE, Parker CM. COPD exacerbations · 3: Pathophysiology. *Thorax*. 2006;61(4):354-61.
99. Giri M, Puri A, Huang L, Guo S. Association between systemic immune-inflammation index and mortality in critically ill patients with chronic obstructive pulmonary disease: insight from the MIMIC-IV database. *Ther Adv Respir Dis*. 2025;19:1-12.
100. Cao Y, Xing Z, Long H, Huang Y, Zeng P, Janssens JP, et al. Predictors of mortality in COPD exacerbation cases presenting to the respiratory intensive care unit. *Respir Res*. 2021;22(77):1-7.
101. Papaioannou AI, Hillas G, Loukides S, Vassilakopoulos T. Mortality prevention as the centre of COPD management. *ERJ Open Res*. 2024;10:1-15.
102. Wang H, Tao Y, Yu X, Chen Z, Ran Y, Wang J, et al. Risk Factors for Length of Hospital Stay in Acute Exacerbation Chronic Obstructive Pulmonary Disease: A Multicenter Cross-Sectional Study. *International Journal of General Medicine*. 2022;15:3447-58.
103. Pokharel P, Lamichhane P, Pant P, Shrestha AB. Factors affecting length of hospital stay in chronic obstructive pulmonary disease patients in a tertiary hospital of Nepal: A retrospective cross-sectional study. *Ann Med Surg*. 2022;80:1-5.
104. Alotaibi TF, Othman F, Alrasheed BA, Aldraiwish BM, Alharthi MM, Alotaibi HG, et al. Length of stay and comorbidity prevalence among individuals with chronic obstructive pulmonary disease in a tertiary care healthcare center in Saudi Arabia; A cross-sectional study. *Med (United States)*. 2025;104(21):1-5.
105. Dong F, Huang K, Ren X, Qumu S, Niu H, Wang Y, et al. Factors associated with inpatient length of stay among hospitalised patients with chronic obstructive pulmonary disease, China, 2016-2017: A retrospective study.

BMJ Open. 2021;11:1-8.

106. Kumar S, Khilnani GC, Banga A, Sharma SK. Predictors of requirement of mechanical ventilation in patients with chronic obstructive pulmonary disease with acute respiratory failure. *Lung India.* 2013;30(3):178-82.
107. Yang H, Huang D, Luo J, Liang Z, Li J. The use of high-flow nasal cannula in patients with chronic obstructive pulmonary disease under exacerbation and stable phases: A systematic review and meta-analysis. *Hear Lung.* 2023;60:116-26.
108. Fadhlurrahman, Wibowo A. Efektivitas Penggunaan Ventilasi Mekanis Non Invasif Pada Pasien Penyakit Paru Obstruktif Kronik Eksaserbasi dengan Ancaman Gagal Napas: Evidence-Based Case Report. *Medula.* 2022;12(3):447-53.
109. Alkhayat K, Abdelhameed R, Gadallah D. The effect of neutrophil-lymphocyte ratio in patients with COPD in Sohag University Hospital. *Egypt J Chest Dis Tuberc.* 2021;70(3):331-6.
110. Furutate R, Ishii T, Motegi T, Hattori K, Kusunoki Y, Gemma A, et al. The neutrophil to lymphocyte ratio is related to disease severity and exacerbation in patients with chronic obstructive pulmonary disease. *Intern Med.* 2016;55:223-9.
111. Sorge R, DeBlieux P. Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Primer for Emergency Physicians. *J Emerg Med.* 2020;59(5):643-59.
112. Alsabani MH, Alotaibi BA, Olayan LH, Alghamdi AS, Alshammasi MA, Alqasir BA, et al. The Value of Preoperative Systemic Immune-Inflammation Index as a Predictor of Prolonged Hospital Stay in Orthopedic Surgery: A Retrospective Study. *Int J Gen Med.* 2023;16:4773-82.
113. Fortis S, Wan ES, Kunisaki K, Eyck PT, Ballas ZK, Bowler RP, et al. Increase mortality associated with frequent exacerbation in COPD patient with mild-to-moderate lung function impairment, and smokers with normal spirometry. Published online 2022. doi:10.1016/j.yrmex.2020.100025.
114. Çolak Y, Afzal S, Marott JL, Nordestgaard BG, Vestbo J, Ingebrigtsen TS,

- et al. Prognosis of COPD depends on severity of exacerbation history: A population-based analysis. *Respir Med.* 2019;155:141-7.
115. Chen X, Wang Q, Hu Y, Zhang L, Xiong W, Xu Y, et al. A nomogram for predicting severe exacerbations in stable COPD patients. *Int J COPD.* 2020;15:379-88.

